BioTuesdays

Category - News

Neuronetics Logo
Markets

Analysts start Neuronetics at OW, OP and buy

Analysts at Piper Jaffray, William Blair and BTIG launched coverage of Neuronetics (NASDAQ:STIM) with “overweight, outperform and buy” ratings, respectively. The stock closed at $26.53 on July 20. “Although the company...

July 23, 2018
Translate Bio Logo
Markets

Leerink starts Translate Bio at OP; PT $24

Leerink initiated coverage of Translate Bio (NASDAQ:TBIO) with an “outperform” rating and $24 price target. The stock closed at $15.94 on July 20. Translate Bio is developing MRT5005, a messenger RNA (mRNA)-based...

July 23, 2018
Mersana Therapeutics Logo
Markets

HCW cuts Mersana Therapeutics PT to $16 from $33

H.C. Wainwright slashed its price target for Mersana Therapeutics (NASDAQ:MRSN) to $16 from $33 after the company disclosed a partial clinical hold on its lead clinical program targeting HER2 expressing cancers. The...

July 20, 2018
Innovate Biopharma logo
Markets

HCW starts Innovate Biopharma at buy; PT $35

H.C. Wainwright initiated coverage of Innovate Biopharmaceuticals (NASDAQ:INNT) with a “buy” rating and $35 price target. The stock finished at $8.08 on July 17. Innovate is focused on two clinical-stage assets aimed at...

July 18, 2018
Autolus Logo
Markets

WB starts Autolus Therapeutics at OP; valuation of $38

William Blair launched coverage of Autolus Therapeutics (NASDAQ:AUTL) with an “outperform” rating and risk-adjusted valuation of roughly $38. The stock closed at $20.86 on July 17. “Based on our view, the company’s next...

July 18, 2018
electroCore Logo
Markets

BTIG starts electroCore at buy; PT $20

BTIG initiated coverage of electroCore (NASDAQ:ECOR) with a “buy” rating and $20 price target. The stock closed at $14.64 on July 16. electroCore has developed an FDA-cleared non-invasive vagus nerve stimulation device...

July 17, 2018
Sol-Gel Logo
Markets

HCW starts Sol-Gel at buy; PT $21

H.C. Wainwright initiated coverage of Sol-Gel Technologies (NASDAQ:SLGL) with a “buy” rating and price target of $21. The stock closed at $6.97 on July 13. The company’s lead drug candidates, TWIN and VERED, are...

July 16, 2018
Kezar Logo
Markets

WB starts Kezar Life Sciences at OP and FVE of $25

William Blair initiated coverage of Kezar Life Sciences (NASDAQ:KZR) with an “outperform” rating and fair value estimate of $25. The stock closed at $16.50 on July 13. Analyst Matthew Phipps writes the company’s novel...

July 16, 2018
Adamas Pharmaceuticals Logo
Markets

HCW starts Adamas Pharma at buy; PT $45

H.C. Wainwright launched coverage of Adamas Pharmaceuticals (NASDAQ:ADMS) with a “buy” rating and $45 price target. The stock closed at $27.06 on July 13. Adamas’ lead product, GOCOVRI, was approved in August 2017 in...

July 16, 2018